Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Breast Cancer Res Treat. 2017 Apr 3;164(1):69–77. doi: 10.1007/s10549-017-4230-8

Fig. 1.

Fig. 1

Relationship between patient-reported sensory symptoms and objective balance measure throughout taxane therapy for the entire cohort (a), relationship between individual patients’ RMS-ml and the transformed CIPN20 sensory subscale values 1–3 months after completing taxane therapy (b)